U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

Levilactobacillus brevis CD2

MORE DETAILS

F9N9W3DON7

structurally diverse
Status:
Investigational
Source:
NCT02357771: Phase 3 Interventional Completed Malocclusion
(2015)
Source URL:
https://clinicaltrials.gov/ct2/show/NCT02357771
Class:
STRUCTURALLY DIVERSE

Levilactobacillus brevis

MORE DETAILS

268IL53Q7O

structurally diverse
Status:
Possibly Marketed Outside US
Source:
ProBionexxProbiotic Support by SKYA HEALTH, LLC
(2023)
Source URL:
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=191954f7-16e4-4707-a891-91b5c1a86ef0
First approved in 2020
Source:
M006
Source URL:
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a350e7b1-d8bf-496c-82dd-b172a854b5ab
Class:
STRUCTURALLY DIVERSE
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966